BioNexus Gene Lab Corp
For the period ended Dec 31, 2025. Filed Apr 14, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Apr 14, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 9B. Other Information
During the quarter ended December 31, 2025, no director or officer of the Company adopted, modified, or terminated any contract, instruction, or written plan for the purchase or sale of the Company’s securities intended to satisfy the affirmative defense conditions of Rule 10b5-1(c), and no director or officer adopted, modified, or terminated any non-Rule 10b5-1 trading arrangement, in each case as defined in Item 408(a) of Regulation S-K.
The Company has adopted insider trading policies and procedures governing the purchase, sale, and other dispositions of the Company’s securities by directors, officers, employees, and the Company itself. These policies and procedures are contained in the Company’s Code of Business Conduct and Ethics. A copy of the Company’s insider trading policies and procedures, as set forth in the Code of Business Conduct and Ethics, is filed as Exhibit 19 to this Annual Report on Form 10-K.
There was no information required to be disclosed in a report on Form 8-K during the quarter ended December 31, 2025 that was not previously reported.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.